← Back to Search

Chemotherapy

CA-4948 + Chemotherapy/Immunotherapy for Stomach & Esophageal Cancer

Phase 1
Recruiting
Led By Patrick Grierson, M.D., Ph.D.
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 18 years of age
Normal bone marrow and organ function criteria
Must not have
Active, known, or suspected autoimmune disease
Live attenuated vaccine within 30 days prior to enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 year
Awards & highlights

Summary

This trial is designed to evaluate the combination of CA-4948 and standard chemo/immunotherapy in untreated gastric and esophageal cancer.

Who is the study for?
Adults with advanced, inoperable or metastatic stomach, gastroesophageal junction, or esophageal cancer. They must not have had previous systemic treatment for their cancer and should be in good physical condition (ECOG 0-1). Participants need normal organ and bone marrow function and known HER2 status. Women of childbearing potential and men must agree to use contraception.
What is being tested?
The trial is testing CA-4948 combined with FOLFOX chemotherapy and a PD-1 inhibitor (nivolumab or pembrolizumab), with an additional option of trastuzumab for those with HER2 positive disease. It includes dose escalation to find the safest dose followed by expansion cohorts based on HER2 status.
What are the potential side effects?
Potential side effects may include reactions related to immune system activation such as inflammation in various organs, infusion-related reactions, fatigue, digestive issues like nausea or diarrhea, blood cell count changes which can affect immunity and healing capacity.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My bone marrow and organs are functioning normally.
Select...
I haven't had systemic treatment for my advanced stomach or esophagus cancer.
Select...
My cancer is in the stomach, gastroesophageal junction, or esophagus and cannot be surgically removed.
Select...
I am fully active or can carry out light work.
Select...
My cancer is HER2 negative.
Select...
My adenocarcinoma's HER2 status is known from a certified lab test.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have an autoimmune disease.
Select...
I have not received a live vaccine in the last 30 days.
Select...
I have a stomach or intestine condition that affects how my body absorbs medication.
Select...
I have brain metastases that are treated and I have no symptoms.
Select...
I am not taking any medications that can cause long QT syndrome.
Select...
I have had an organ or stem cell transplant from a donor.
Select...
I haven't taken steroids or immunosuppressants in the last 14 days.
Select...
I do not have any uncontrolled illnesses.
Select...
I have a lung condition that is moderate to severe.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Disease control rate (DCR)
Overall response rate (ORR) per RECIST 1.1
Overall response rate (ORR) per iRECIST
+3 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dose Expansion Cohort B (CA4948 + FOLFOX + Pembrolizumab + Trastuzumab)Experimental Treatment4 Interventions
* CA4948 (dose will be the recommended dose found in the dose escalation portion of study) twice daily by mouth Standard of care mFOLFOX7 every 14 days. Pembrolizumab on day 1 of every 3 cycles. Trastuzumab every 14 days. * Each cycle is 14 days.
Group II: Dose Expansion Cohort A (CA4948 + FOLFOX + Nivolumab)Experimental Treatment3 Interventions
* CA4948 (dose will be the recommended phase II dose found in the dose escalation portion of study) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days. * Each cycle is 14 days.
Group III: Dose Escalation (CA4948 + FOLFOX + Nivolumab)Experimental Treatment3 Interventions
* CA4948 (dose will depend on dose level assigned) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days. * Each cycle is 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trastuzumab
2014
Completed Phase 4
~5190
mFOLFOX7
2018
Completed Phase 2
~130
Pembrolizumab
2017
Completed Phase 2
~2070
Nivolumab
2014
Completed Phase 3
~5220

Find a Location

Who is running the clinical trial?

The Foundation for Barnes-Jewish HospitalOTHER
40 Previous Clinical Trials
6,380 Total Patients Enrolled
Curis, Inc.Industry Sponsor
16 Previous Clinical Trials
1,026 Total Patients Enrolled
Washington University School of MedicineLead Sponsor
1,970 Previous Clinical Trials
2,308,581 Total Patients Enrolled

Media Library

5-FU (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT05187182 — Phase 1
Esophageal Cancer Research Study Groups: Dose Expansion Cohort B (CA4948 + FOLFOX + Pembrolizumab + Trastuzumab), Dose Escalation (CA4948 + FOLFOX + Nivolumab), Dose Expansion Cohort A (CA4948 + FOLFOX + Nivolumab)
Esophageal Cancer Clinical Trial 2023: 5-FU Highlights & Side Effects. Trial Name: NCT05187182 — Phase 1
5-FU (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05187182 — Phase 1
~26 spots leftby Sep 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top